Entrada Therapeutics (TRDA)
NasdaqMercado abierto
6.43USD
−0.06(-0.92%)
Última actualización
- Capitalización
- $277,618,450
- PER
- —
- Precio/FCF
- —
- Precio/Ventas
- 59.24
- Valor de empresa
- $178,338,450
- Sector de actividad
- —
- Industria
- —
- Dirección
- ONE DESIGN CENTER PLACE, BOSTON, MA, 02210
globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 jun 2026, 22:30 P. M.
yahoo.com
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
07 may 2026, 22:04 P. M.
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
07 may 2026, 21:44 P. M.
yahoo.com
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
05 may 2026, 15:12 P. M.
yahoo.com
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
04 may 2026, 23:10 P. M.
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
06 abr 2026, 21:50 P. M.
yahoo.com
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
18 mar 2026, 19:08 P. M.
nasdaq.com
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
18 mar 2026, 19:08 P. M.
yahoo.com
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
18 mar 2026, 18:54 P. M.
globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mar 2026, 22:30 P. M.
yahoo.com
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
26 feb 2026, 01:25 A. M.
yahoo.com
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
24 feb 2026, 15:40 P. M.
yahoo.com
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates
06 feb 2026, 00:00 A. M.
yahoo.com
Techne (TECH) Beats Q2 Earnings and Revenue Estimates
04 feb 2026, 13:40 P. M.
globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 dic 2025, 22:30 P. M.
nasdaq.com
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
29 nov 2025, 19:48 P. M.
yahoo.com
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
29 nov 2025, 19:48 P. M.
yahoo.com
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
18 nov 2025, 20:11 P. M.
yahoo.com
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out
18 nov 2025, 19:55 P. M.
yahoo.com
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
06 nov 2025, 14:30 P. M.
- Capitalización
La capitalización bursátil es el valor total de las acciones de una empresa, calculado multiplicando el precio por el número de acciones en circulación.
- $277,618,450
- Valor de empresa
El valor de empresa es el valor total de una compañía, incluyendo capitalización, deuda y efectivo.
- $178,338,450
- PER
El PER compara el precio de la acción con el beneficio por acción.
- —
- Precio/Valor contable
El ratio P/B compara el precio de la acción con su valor contable por acción.
- 1.19
- Precio/Ventas
El ratio P/S compara el precio de la acción con los ingresos por acción.
- 59.24
- VE / EBITDA
VE/EBITDA mide el valor de una empresa respecto a su resultado antes de intereses, impuestos, depreciación y amortización.
- -1.03
- VE / Ventas
VE/Ventas mide el valor de una empresa respecto a sus ingresos totales.
- 38.06
- BPA
- -4.26
- Rendimiento por dividendo
El rendimiento por dividendo muestra cuánto paga una empresa en dividendos al año respecto al precio de la acción.
- 0%
- Precio/FCF
El ratio precio/flujo de caja libre compara el precio de la acción con el efectivo generado tras gastos e inversiones.
- —
- Precio/Flujo de caja
El ratio P/CF compara el precio de la acción con el flujo de caja de las operaciones.
- —
- Flujo de caja libre
El flujo de caja libre es el efectivo que queda tras cubrir costes operativos y gastos de capital.
- -$134,997,000
- Rent. sobre fondos propios
El ROE mide la eficacia con la que una empresa utiliza el patrimonio neto para generar beneficios.
- -71.02%
- Rent. sobre activos
El ROA mide la eficacia con la que una empresa utiliza sus activos para generar beneficios.
- -55.47%
- Deuda / Patrimonio
El ratio deuda/patrimonio compara la deuda total con el patrimonio neto.
- 0
- Ratio corriente
El ratio corriente mide la capacidad de una empresa para pagar deudas a corto plazo con activos corrientes.
- 10.89
- Prueba ácida
La prueba ácida mide la capacidad de pagar deudas a corto plazo con efectivo y activos fácilmente realizables.
- 10.89
- Efectivo
El ratio de efectivo mide la capacidad de cubrir deudas a corto plazo solo con efectivo y equivalentes.
- 4.65
- Vol. medio
El volumen medio muestra el número promedio de acciones negociadas en los últimos 30 días de bolsa, útil para evaluar la liquidez.
- $329,059
- Precio de referencia fundamental
El precio de referencia fundamental es el precio de la acción usado al calcular los ratios financieros.
- 7.13
Cuenta de resultados
| Partida | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Ingresos | 898K | 875K | 1.3M | 1.61M | 1.95M |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Beneficio bruto | 898K | 875K | 1.3M | 1.61M | 1.95M |
| Resultado operativo | -44.96M | -42.3M | -42.21M | -47.05M | -46.85M |
| EBITDA operativo | -44.12M | -41.5M | -41.32M | -45.82M | -45.82M |
| Beneficio neto | -42.76M | -39.72M | -39.16M | -44.13M | -43.1M |
| Income taxes | 35K | 38K | 92K | 654K | 178K |
| Interest expense | 0 | 0 | 0 | 0 | 0 |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 45.86M | 43.18M | 43.51M | 48.67M | 48.8M |
| BPA básico | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
| BPA diluido | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
Balance
| Partida | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Activos totales | 298.88M | 335.52M | 377.38M | 412.9M | 448.78M |
| Pasivos totales | 65.47M | 64.66M | 71.25M | 72.18M | 69.28M |
| Patrimonio neto | 233.41M | 270.85M | 306.13M | 340.72M | 379.51M |
| Efectivo y equivalentes | 99.28M | 76.44M | 90.39M | 93.29M | 72.48M |
| Activos corrientes | 232.7M | 266.87M | 306.25M | 338.26M | 369.15M |
| Pasivos corrientes | 21.37M | 19.2M | 24.45M | 24.02M | 19.8M |
| Accounts payable | 3.75M | 2.93M | 2.29M | 3.17M | 1.86M |
| Receivables | 816K | 787K | 1.18M | 1.2M | 1.18M |
| Inventories | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
Flujo de caja
| Partida | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Flujo de caja operativo | -32.46M | -41.7M | -32.2M | -28.31M | -29.49M |
| Flujo de caja de inversión | 54.95M | 26.99M | 29.12M | 49.11M | 33.8M |
| Flujo de caja de financiación | 350K | 100K | 192K | 8K | 337K |
| Variación de efectivo | 22.84M | -14.61M | -2.89M | 20.8M | 4.65M |
| Beneficio neto | -42.76M | -39.72M | -39.16M | -44.13M | -43.1M |
| Tipo | Informe | Fecha | Enlace |
|---|---|---|---|
| edgar index | SCHEDULE 13D/A — Entrada Therapeutics, Inc. | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | Ver informe | |
| form 4 | Form 4 — Foley Todd | Ver informe | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | Ver informe | |
| form 4 | Form 4 — EVNIN LUKE | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | Ver informe | |
| form 4 | Form 4 — GADICKE ANSBERT | Ver informe | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | Ver informe | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | Ver informe | |
| form 4 | Form 4 — EVNIN LUKE | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | Ver informe | |
| form 4 | Form 4 — GADICKE ANSBERT | Ver informe | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | Ver informe | |
| form 4 | Form 4 — Foley Todd | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | Ver informe | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | Ver informe | |
| form 4 | Form 4 — Foley Todd | Ver informe | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | Ver informe | |
| form 4 | Form 4 — EVNIN LUKE | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | Ver informe | |
| form 4 | Form 4 — GADICKE ANSBERT | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| edgar index | 4 — Entrada Therapeutics, Inc. | Ver informe | |
| form 4 | Form 4 — Foley Todd | Ver informe | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | Ver informe | |
| form 4 | Form 4 — EVNIN LUKE | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | Ver informe | |
| form 4 | Form 4 — GADICKE ANSBERT | Ver informe | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | Ver informe | |
| form 4 | Form 4 — EVNIN LUKE | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | Ver informe | |
| form 4 | Form 4 — GADICKE ANSBERT | Ver informe | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | Ver informe | |
| form 4 | Form 4 — Foley Todd | Ver informe | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | Ver informe | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | Ver informe | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | Ver informe | |
| form 4 | Form 4 — Doshi Dipal | Ver informe |
Intervalo